EpiPen buyers leading a class action against various Mylan defendants are seeking Kansas federal court approval for a $264 million settlement that, together with a previous settlement with defendant Pfizer, brings their total recovery to $609 million.
The agreement is substantially similar to the court-approved
It provides that
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.